William Blair Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform

Raymond James Comments on Biohaven (BHVN) Post Management Call

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $54.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "Remain Strong Buy rated on BHVN shares and are herein adjusting our model after catching up with CEO Vlad Coric... More

JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'

JPMorgan analyst Tessa Romero reiterated an Overweight rating and $47.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "We are disappointed, though not necessarily surprised, to see that Vyglxia (troriluzole)s NDA for the treatment of spinocerebellar ataxia (SCA) received a Complete Response Letter (CRL) today as we and the market had been more cautious around the likelihood of approval given 1) the current uncertain and evolving regulatory environment, 2) recent decisions involving RWE/the utilization of natural history cohorts, 3) the unavailability of the... More

William Blair on Biohaven (BHVN): 'Expect Weakness'

William Blair analyst Myles Minter reiterated an Outperform rating and {REMOVEPT} price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "Our Take: Biohaven shares were down 19% after market, and we expect material weakness in response to the CRL and potential liquidity... More

Morgan Stanley on Biohaven (BHVN): 'The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2/3 data in major depressive disorder (MDD)'

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $54.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "Per the BHVN press release (LINK), the FDA cited issues that can be inherent to real-world evidence and external control studies including potential bias, design flaws, lack of pre-specification and unmeasured confounding factors. In the CRL, the FDA recommended that Biohaven meet with the Division to discuss the... More

Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'

Raymond James analyst Chris Raymond lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $54.00 (from $75.00) while maintaining a Strong Buy rating.

The analyst comments "Remain Strong Buy rated on BHVN shares but also understand this name... More

Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird

(Updated - November 5, 2025 6:10 AM EST)

Baird analyst Brian Skorney lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $42.00 (from $52.00) while maintaining a Outperform rating.

The analyst commented: "Lowering target to $42 on FDA rejection. A clear negative,... More

Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at TD Cowen

TD Cowen analyst Tyler Van Buren lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $15.00 (from $50.00) while maintaining a Buy rating.... More

FDA rejects Biohaven drug application for rare brain disorder

Biohaven Ltd. (NYSE: BHVN) received a complete response letter from the U.S. Food and Drug Administration rejecting its new drug application for VYGLXIA (troriluzole) to treat spinocerebellar ataxia, the company announced.

The FDA cited concerns about potential bias, design flaws, and unmeasured confounding factors in Biohaven's real-world evidence... More

Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'

Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'.

The analyst comments "This AM, Uniqure (QURE, NR) shared that based on recent pre-BLA mtg, the FDA is unlikely to approve AMT-130 with current data package (PR HERE). Based on our prior conversations with thought leaders in HD, this may, at least in part, be related to the use of ENROLL-HD natural history as matched control. This is a unique issue for QURE with no read-throughs to PTCT & WVE's HD programs, in our view. Recall, prior disclosures from QURE implied that the FDA would accept matched patients from... More

Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $75.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN)

The analyst comments "While we continue to characterize this quarters PDUFA decision on troriluzole in SCA as high-risk, we think todays premarket action (down ~25%) seemingly in sympathy to QUREs contention that FDA reversed itself relative to the submission of AMT-130 (a gene therapy for Huntingtons disease) is misplaced. For starters, we are... More

Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease

Biohaven Pharma (NYSE: BHVN) Weakness May Be Tied to uniQure (NASDAQ: QURE) Setback in Huntington's Disease